Yahoo Finance 
Hospital Acquired Infections Testing Kits Global Market Report 2022
Major players in the hospital-acquired infections testing kits market are Becton, Dickinson and Company, Abott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd. , Hologic, Roche, Bayer AG, Cantel Medical Corporation, and Meridian Bioscience.
New York, May 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hospital Acquired Infections Testing Kits Global Market Report 2022" - https://www.reportlinker.com/p06280836/?utm_source=GNW
The global hospital acquired infections testing kits market is expected to grow from $1.12 billion in 2021 to $1.27 billion in 2022 at a compound annual growth rate (CAGR) of 12.7%. The market is expected to grow to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%.
The hospital-acquired infections testing kits market consists of sales of hospital-acquired infections testing kits, devices, and related services. Hospital-acquired infections testing kits are used to check the infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and clostridium difficile.
The main products of hospital-acquired infections testing kits are instruments and reagents, and consumables.The hospital-acquired infections testing kit instruments involves the various instruments that are required for hospital-acquired infections testing to aid scientist in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing.
The pathogens tested using hospital-acquired infections testing kits are viral, bacterial, and fungal by sterilization, chemical, and radiation method of treatment to test pneumonia infection, urinary tract infection, bloodstream associated infection, surgical site infection, MRSA infection, and others. The various applications include drug-resistance testing and disease testing.
The hospital-acquired infections (HAIs) are on the rise, affecting both the inpatients and outpatients.Hospital-acquired infections or nosocomial infections are diseases that are acquired in hospitals and medical clinics.
For example, according to the findings by the Center for Disease Control and Prevention, around 1.7 million people in the USA acquire hospital-acquired infections caused while being admitted for other health issues and more than 98,000 (around 5%) patients die due to these infections. The increasing incidence of hospital-acquired infections leads to an increase in the demand for hospital-acquired infections testing kits.
Most of the underdeveloped and developing nations lack proper health insurance that covers essential health services.According to a report by the World Bank and the World Health Organization, more than 50% of the world’s population cannot avail of essential health services due to expensive healthcare services that push them to poverty.
For instance, 800 million people spend more than 10% of their household budgets on health expenses for themselves, a sick child, or other family members, and for almost 100 million people these expenses are high enough to push them into extreme poverty. This lack of financially affordable healthcare hinders the market growth for diagnostic services including hospital-acquired infection testing.
The diagnostic tests involved in diagnosing HAIs such as flow cytometry, mass spectrometry, near-infrared spectroscopy, nucleic acid-based technologies are advancing in technologies, providing more accurate data.There has been a significant advancement in mass spectrometers, which quantifies known materials, and identifies unknown compounds within a sample.
For instance, SCIEX’s X500 QTOF solves the challenge of contamination and is a compact device that does not compromise on resolution and accuracy. It gives results sooner and allows the operator to make data-driven decisions sooner.
The hospital-acquired infections testing kits are regulated by government agencies such as US FDA (Food and Drug Administration) in the USA, and the European Medicines Agency/Committee in European Region.The regulatory body lays down a set of guidelines pertaining to the safety, efficiency, and efficacy of the instruments that form part of the hospital-acquired infection testing kits market.
The manufacturers and service providers must comply with the CBER Regulations that have been published in the first chapter Title 21 of CFR.Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories.
The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose.CBER comes under FDA (Food and Drug Administration).
Also, Code of Federal Regulations Title 21, Part 866 states regulations pertaining to immunology and microbiology devices. These devices are used to identify infections caused due to bacteria and various viruses.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the hospital-acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Read the full report: https://www.reportlinker.com/p06280836/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
